مؤتمر
Presentation1_Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients.pdf
| العنوان: | Presentation1_Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients.pdf |
|---|---|
| المؤلفون: | Danhong Liang, Zhi Liang, Guoliang Deng, Anfen Cen, Dandan Luo, Chen Zhang, Suiqin Ni |
| سنة النشر: | 2023 |
| المجموعة: | Frontiers: Figshare |
| مصطلحات موضوعية: | Pharmacology, Basic Pharmacology, Clinical Pharmacology and Therapeutics, Clinical Pharmacy and Pharmacy Practice, Pharmaceutical Sciences, Pharmacogenomics, Toxicology (incl. Clinical Toxicology), Pharmacology and Pharmaceutical Sciences not elsewhere classified, polymyxin B, critically ill patients, population pharmacokinetics, albumin levels, dosing optimization |
| الوصف: | Objectives: Since the global broadcast of multidrug-resistant gram-negative bacteria is accelerating, the use of Polymyxin B is sharply increasing, especially in critically ill patients. Unsatisfactory therapeutic effects were obtained because of the abnormal physiological function in critically ill patients. Therefore, the determination of optimal polymyxin B dosage becomes highly urgent. This study aimed to illustrate the polymyxin B pharmacokinetic characteristics by defining the influencing factors and optimizing the dosing regimens to achieve clinical effectiveness. Methods: Steady-state concentrations of polymyxin B from twenty-two critically ill patients were detected by a verified liquid chromatography-tandem mass spectrometry approach. The information on age, weight, serum creatinine, albumin levels, and Acute Physiology and Chronic Health Evaluation-II (APACHE-II) score was also collected. The population PK parameters were calculated by the non-parametric adaptive grid method in Pmetrics software, and the pharmacokinetic/pharmacodynamics target attainment rate was determined by the Monte Carlo simulation method. Results: The central clearance and apparent volume of distribution for polymyxin B were lower in critically ill patients (1.24 ± 0.38 L h -1 and 16.64 ± 12.74 L, respectively). Moreover, albumin (ALB) levels can be used to explain the variability in clearance, and age can be used to describe the variability in the apparent volume of distribution. For maintaining clinical effectiveness and lowering toxicity, 75 mg q12 h is the recommended dosing regimen for most patients suffering from severe infections. Conclusion: This study has clearly defined that in critically ill patients, age and ALB levels are potentially important factors for the PK parameters of polymyxin B. Since older critically ill patients tend to have lower ALB levels, so higher dosages of polymyxin B are necessary for efficacy. |
| نوع الوثيقة: | conference object |
| اللغة: | unknown |
| العلاقة: | https://figshare.com/articles/presentation/Presentation1_Population_pharmacokinetic_analysis_and_dosing_optimization_of_polymyxin_B_in_critically_ill_patients_pdf/22351885Test |
| DOI: | 10.3389/fphar.2023.1122310.s002 |
| الإتاحة: | https://doi.org/10.3389/fphar.2023.1122310.s002Test https://figshare.com/articles/presentation/Presentation1_Population_pharmacokinetic_analysis_and_dosing_optimization_of_polymyxin_B_in_critically_ill_patients_pdf/22351885Test |
| حقوق: | CC BY 4.0 |
| رقم الانضمام: | edsbas.AFC2BEDA |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fphar.2023.1122310.s002 |
|---|